Clopidogrel Bisulfate
Product Images NDC 69117-1010

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 69117-1010). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Yiling Pharmaceutical,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

4ec4203e F1f8 0398 E054 00144ff88e88

Clopidogrel bisulfate round pink tablets imprinted with 'SG' on one side and '124' on the other side. No additional package or label information is visible. Manufactured by YILING PHARMACEUTICAL, INC.*

FDA Label Image

75mg-1000s (75mg 1000s)

Label for Clopidogrel tablets, USP 75 mg, manufactured by ScieGen Pharmaceuticals, Inc. and distributed by Yiling Pharmaceutical, Inc. The label indicates a supply of 1,000 tablets, contains dosage and storage instructions, a barcode, and the Yiling Pharmaceutical logo. The label dimensions are 6.0 inches by 2.5 inches.*

FDA Label Image

75mg-30s (75mg 30s)

Label for Clopidogrel tablets USP 75 mg manufactured by Yiling Pharmaceutical, Inc. The label indicates a package of 30 tablets, marked Rx Only. The label also includes storage instructions, dosage guidance referring to the package insert, manufacturer and distributor information, and a barcode with NDC number 69117-1010-1. The label dimensions are indicated as 3.5 inches long by 1.5 inches wide.*

FDA Label Image

75mg-500s (75mg 500s)

Label for Clopidogrel Tablets, USP 75 mg by Yiling Pharmaceutical, Inc. The label shows the product name and strength prominently in white text on a blue background, indicating 500 tablets and Rx only. It includes manufacturer and distributor information, dosage form, NDC 69117-1010-3, and a barcode on a white background.*

FDA Label Image

75mg-90s (75mg 90s)

Label for Clopidogrel bisulfate tablets, USP, 75 mg strength, with 90 tablets per bottle. The label prominently displays the brand name Clopidogrel and dosage strength. It includes storage instructions, manufacturer (Solegen Pharmaceuticals, Inc.), and distributor information (Yiling Pharmaceutical, Inc.). The label also shows the NDC number 69117-1010-2 and has a barcode. The packaging label is primarily blue and white with red and black text.*

FDA Label Image

Figure 1 (Figure 1)

A horizontal error bar chart showing the effect of four proton pump inhibitors (dexlansoprazole 60 mg, lansoprazole 30 mg, pantoprazole 80 mg, omeprazole 80 mg) on the exposure to clopidogrel active metabolite AUC following multiple doses of clopidogrel 75 mg. The x-axis represents change relative to clopidogrel administered alone, ranging approximately from 0.4 to 1.4, with mean and 90% confidence intervals for each inhibitor.*

FDA Label Image

Figure 2 (Figure 2)

A line graph titled 'Cardiovascular Death, Myocardial Infarction, Stroke in the CURE Study' showing cumulative event rate percentages over 12 months of follow up. Two lines represent occurrence rates for Placebo (+ aspirin) and Clopidogrel (+ aspirin), with the Clopidogrel line lower than Placebo, and a P-value of 0.00009 indicated. A footnote states that other standard therapies were used as appropriate.*

FDA Label Image

Figure 3 (Figure 3)

A hazard ratio forest plot chart illustrating patient baseline characteristics and on-study concomitant medications/interventions for the CURE study involving Clopidogrel bisulfate. The chart compares subgroups by age, gender, race, enzyme elevation, diabetes, previous MI and stroke, and use of medications like Heparin/LMWH, aspirin, GP IIb/IIIa antagonists, beta-blockers, and ACE inhibitors. It shows hazard ratios with 95% confidence intervals for favoring Clopidogrel versus placebo.*

FDA Label Image

Figure 4 (Figure 4)

A Kaplan-Meier survival curve comparing the percentage of deaths before first discharge over 28 days between placebo and Clopidogrel groups, showing 8.1% deaths in the placebo group and 7.5% deaths in the Clopidogrel group, with a 7% proportional risk reduction (p=0.03).*

FDA Label Image

Figure 5 (Figure 5)

A Kaplan-Meier curve graph showing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. The graph compares placebo and Clopidogrel groups, indicating event percentages (10.1% placebo, 9.2% Clopidogrel) and a 9% proportional risk reduction with Clopidogrel (p=0.002).*

FDA Label Image

Figure 6 (Figure 6)

A forest plot chart comparing odds ratios for the effect of Clopidogrel bisulfate versus placebo across various subgroups by gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent use. The chart displays odds ratios with 99% confidence intervals and highlights an overall odds ratio with a 95% confidence interval for the entire study population.*

FDA Label Image

Figure 7 (Figure 7)

A line graph showing cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up. It compares two treatment groups labeled as Aspirin and Clopidogrel, with event rates increasing over time and a P-value of 0.045 indicating statistical comparison between groups.*

FDA Label Image

Figure 8 (Figure 8)

A forest plot chart comparing the hazard ratio (with 95% confidence intervals) of Clopidogrel versus Aspirin across various qualifying conditions: Stroke, MI (myocardial infarction), PAD (peripheral artery disease), and Overall. The x-axis represents the hazard ratio ranging from 0.6 to 1.3, with markers showing whether data favors Clopidogrel or Aspirin.*

FDA Label Image

Structural Formula (Structural Formula)

Chemical structure of clopidogrel bisulfate showing its molecular composition, including a thiophene ring, a chlorophenyl group, and the bisulfate moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.